Skip to main content

Survival following allogeneic transplant in patients with myelofibrosis.

Publication ,  Journal Article
Gowin, K; Ballen, K; Ahn, KW; Hu, Z-H; Ali, H; Arcasoy, MO; Devlin, R; Coakley, M; Gerds, AT; Green, M; Gupta, V; Hobbs, G; Jain, T; Seo, S ...
Published in: Blood advances
May 2020

Allogeneic hematopoietic cell transplantation (HCT) is the only curative therapy for myelofibrosis (MF). In this large multicenter retrospective study, overall survival (OS) in MF patients treated with allogeneic HCT (551 patients) and without HCT (non-HCT) (1377 patients) was analyzed with Cox proportional hazards model. Survival analysis stratified by the Dynamic International Prognostic Scoring System (DIPSS) revealed that the first year of treatment arm assignment, due to upfront risk of transplant-related mortality (TRM), HCT was associated with inferior OS compared with non-HCT (non-HCT vs HCT: DIPSS intermediate 1 [Int-1]: hazard ratio [HR] = 0.26, P < .0001; DIPSS-Int-2 and higher: HR, 0.39, P < .0001). Similarly, in the DIPSS low-risk MF group, due to upfront TRM risk, OS was superior with non-HCT therapies compared with HCT in the first-year post treatment arm assignment (HR, 0.16, P = .006). However, after 1 year, OS was not significantly different (HR, 1.38, P = .451). Beyond 1 year of treatment arm assignment, an OS advantage with HCT therapy in Int-1 and higher DIPSS score patients was observed (non-HCT vs HCT: DIPSS-Int-1: HR, 2.64, P < .0001; DIPSS-Int-2 and higher: HR, 2.55, P < .0001). In conclusion, long-term OS advantage with HCT was observed for patients with Int-1 or higher risk MF, but at the cost of early TRM. The magnitude of OS benefit with HCT increased as DIPSS risk score increased and became apparent with longer follow-up.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Blood advances

DOI

EISSN

2473-9537

ISSN

2473-9529

Publication Date

May 2020

Volume

4

Issue

9

Start / End Page

1965 / 1973

Related Subject Headings

  • Transplantation, Homologous
  • Retrospective Studies
  • Prognosis
  • Primary Myelofibrosis
  • Humans
  • Hematopoietic Stem Cell Transplantation
  • 3201 Cardiovascular medicine and haematology
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Gowin, K., Ballen, K., Ahn, K. W., Hu, Z.-H., Ali, H., Arcasoy, M. O., … Saber, W. (2020). Survival following allogeneic transplant in patients with myelofibrosis. Blood Advances, 4(9), 1965–1973. https://doi.org/10.1182/bloodadvances.2019001084
Gowin, Krisstina, Karen Ballen, Kwang Woo Ahn, Zhen-Huan Hu, Haris Ali, Murat O. Arcasoy, Rebecca Devlin, et al. “Survival following allogeneic transplant in patients with myelofibrosis.Blood Advances 4, no. 9 (May 2020): 1965–73. https://doi.org/10.1182/bloodadvances.2019001084.
Gowin K, Ballen K, Ahn KW, Hu Z-H, Ali H, Arcasoy MO, et al. Survival following allogeneic transplant in patients with myelofibrosis. Blood advances. 2020 May;4(9):1965–73.
Gowin, Krisstina, et al. “Survival following allogeneic transplant in patients with myelofibrosis.Blood Advances, vol. 4, no. 9, May 2020, pp. 1965–73. Epmc, doi:10.1182/bloodadvances.2019001084.
Gowin K, Ballen K, Ahn KW, Hu Z-H, Ali H, Arcasoy MO, Devlin R, Coakley M, Gerds AT, Green M, Gupta V, Hobbs G, Jain T, Kandarpa M, Komrokji R, Kuykendall AT, Luber K, Masarova L, Michaelis LC, Patches S, Pariser AC, Rampal R, Stein B, Talpaz M, Verstovsek S, Wadleigh M, Agrawal V, Aljurf M, Angel Diaz M, Avalos BR, Bacher U, Bashey A, Beitinjaneh AM, Cerny J, Chhabra S, Copelan E, Cutler CS, DeFilipp Z, Gadalla SM, Ganguly S, Grunwald MR, Hashmi SK, Kharfan-Dabaja MA, Kindwall-Keller T, Kröger N, Lazarus HM, Liesveld JL, Litzow MR, Marks DI, Nathan S, Nishihori T, Olsson RF, Pawarode A, Rowe JM, Savani BN, Savoie ML, Seo S, Solh M, Tamari R, Verdonck LF, Yared JA, Alyea E, Popat U, Sobecks R, Scott BL, Nakamura R, Mesa R, Saber W. Survival following allogeneic transplant in patients with myelofibrosis. Blood advances. 2020 May;4(9):1965–1973.

Published In

Blood advances

DOI

EISSN

2473-9537

ISSN

2473-9529

Publication Date

May 2020

Volume

4

Issue

9

Start / End Page

1965 / 1973

Related Subject Headings

  • Transplantation, Homologous
  • Retrospective Studies
  • Prognosis
  • Primary Myelofibrosis
  • Humans
  • Hematopoietic Stem Cell Transplantation
  • 3201 Cardiovascular medicine and haematology